Pharma BD Deal Intelligence

Pathos AI, Inc. / AstraZeneca PLC

2026 · Licensing/Option · Pending

On August 3, 2026, Pathos AI entered a co-exclusive licensing agreement with AstraZeneca for AZD4241, a preclinical oral PROTAC targeted protein degrader for ER+/HER2- breast cancer. Pathos assumes responsibility for early clinical development. Financial terms were not disclosed. The agreement was announced alongside, but is separate from, Pathos AI's licensing deal with Alphamab Oncology for JSKN016. NOTE: ingested at pending_review by bd-enrichment 2026-08-05.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Pathos AI, Inc. deals